Palbociclib (PD-0332991) HCl Licensed by Pfizer

Catalog No.S1116

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Price Stock Quantity  
USD 110 In stock
USD 170 In stock
USD 570 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Palbociclib (PD-0332991) HCl Chemical Structure

Palbociclib (PD-0332991) HCl Chemical Structure
Molecular Weight: 483.99

Validation & Quality Control

6 customer reviews :

Quality Control & MSDS

Related Compound Libraries

CDK Inhibitors with Unique Features

  • Pan CDK Inhibitor

    BAY 1000394 Pan-CDK1/2/3/4/7/9 inhibitor, IC50=5-25 nM.

  • Most Potent CDK Inhibitor

    LY2835219 CDK4, IC50=2 nM; CDK6, IC50=10 nM.

  • CDK Inhibitor in Clinical Trial

    Dinaciclib (SCH727965) Phase III for Chronic Lymphocytic Leukemia (CLL).

  • Newest CDK Inhibitor

    NU6027 Potent ATR/CDK inhibitor, inhibits CDK1/2, ATR and DNA-PK with Ki of 2.5 μM/1.3 μM, 0.4 μM and 2.2 μM, enter cells more readily than the 6-aminopurine-based inhibitors.

Product Information

  • Compare CDK Inhibitors
    Compare CDK Products
  • Research Area
  • Inhibition Profile

Product Description

Biological Activity

Description Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.
Targets CDK4/CyclinD3 [1]
(Cell-free assay)
CDK4/CyclinD1 [1]
(Cell-free assay)
CDK6/CyclinD2 [1]
(Cell-free assay)
CDK2/CyclinE2 [1]
(Cell-free assay)

 View  More

IC50 9 nM 11 nM 15 nM >10 μM
In vitro PD 0332991 has little effect on other protein kinases including EGFR, FGFR, PGFR, IR. PD 0332991 is a non-ATP competitive inhibitor of Cdk4. PD 0332991 inhibits MDA-MB-435 breast carcinoma cells with IC50 of 66 nM, which is due to reduced Rb phosphorylation at Ser780. PD 0332991 inhibits thymidine incorporation into the DNA of Rb-positive human breast, colon, and lung carcinomas as well as human leukemias, with IC50 values ranging from 0.04-0.17 μM. PD 0332991 shows no activity in Rb-negative cells. PD 0332991 causes an accumulation of cells in G1 in MDA-MB-453 breast and Colo-205 carcinoma cells. [1] PD 0332991 also shows activity in 5T33MM myeloma cells (immunocompetent model) and sensitizes the cells to killing by bortezomib. [2] PD 0332991 inhibits luminal ER-positive as well as HER2-amplified breast cancer cell lines including MDA-MB-175, ZR-75-30, CAMA-1, MDA-MB-134, HCC-202 and UACC-893. PD 0332991 enhances the activity of tamoxifen and trastuzumab in these cell lines. PD 0332991 enhances the sensitivity of tamoxifen in the MCF7 tamoxifen-resistant cells. [3] A recent study shows that PD 0332991 could suppress malignant rhabdoid tumor (MRT) cell lines including MP-MRT-AN, KP-MRT-RY, G401, KP-MRT-NS and the sensitivity of the MRT cell lines to PD 0332991 is inversely correlated with expression of p16. [4]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
MOLM13M3H1UmtqdmG|ZTDBd5NigQ>?M1XKTVI1KGh?MXHJcohq[mm2aX;uJI9nKEOGS{SgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDSZkBxcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwMECyJO69VQ>?M3HNdlI1PjRzMUCz
COLO205NVLocmtxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVzrU2doPzJiaB?=MmT5RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{\XO|ZXSgZZMhcW6lb4Lwc5JifGmxbjDv[kBcO0ifdHj5cYllcW6nIHnueI8hTE6DIIfpeIghUUN3MDDv[kAxNjB|NjFOwG0>MlHDNlQ3PDFzMEO=
U937NFfXV3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3S2W|czKGh?M4HjZmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2W|c3XkJIF{KGmwY3;ydI9z[XSrb36gc4YhYzOKXYTofY1q\GmwZTDpcpRwKESQQTD3bZRpKEmFNUCgc4YhOC5zNDFOwG0>MVOyOFY1OTFyMx?=
MOLM13MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmTFO|IhcA>?MnOxRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPT1zNNVMh[2WubIOgbIFz[m:{aX7nJGZNXDNiSWTEJI12fGGwdDDhd5Nme3OnZDDhd{BqdmOxcoDvdoF1cW:wIH;mJHs{UF22aIntbYRqdmViaX70c{BFVkFid3n0bEBKSzVyIH;mJFAvODl4IN88US=>MnqwNlQ3PDFzMEO=
MOLM13Mlm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mk[yO|IhcA>?NGHPUJpCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JJNwemGoZX7pZk1z\XOrc4ThcpQhcHWvYX6gUW9NVTF|IHPlcIx{KGG|c3Xzd4VlKGG|IHnuZ49zeG:{YYTpc44hd2ZiW{PIYZRpgW2rZHnu[UBqdnSxIFTORUB4cXSqIFnDOVAhd2ZiMD6wPVYh|ryPNWLzOVRtOjR4NEGxNFM>
MDA-MB-435MlHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYOyOEBpNV7QeHR1UUN3ME2wMlE3KM7:TR?=NHnmTogyPThyMUizNS=>
K562M4exTmN6fG:2b4jpZ{BCe3OjeR?=NXTqTIpJQTZiaB?=NUXFSJdMTE2VTx?=MX3JR|UxRTJizszNM3rFUFI1PDF5NU[2
DU145NGjUWVJEgXSxdH;4bYMhSXO|YYm=NILKc3Q6PiCqM{fneGROW09?M32wcGlEPTB;Nz61JO69VQ>?NI\KNWMzPDRzN{W2Oi=>
MDA-MB-231NGKwfndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIjUeWwyKM7:TR?=NG\HNFEzPCCqNEHrT5BFVVORNULxcno3S2WubDDjfYNt\SCjcoLld5Qh[XO|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJIF1KEdzIIDoZZNmNXv0T5g3OjR2MUe1OlY>
MCF7NXe4TIwxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MorUNUDPxE1?M3HvT|I1KGh?MlzSSG1UVw>?Mn6zR4VtdCCleXPs[UBienKnc4SgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIHH0JGcyKHCqYYPlNEjOdIEzPDRzN{W2Oi=>
MCF7NFrUSFVMcW6jc3WgRZN{[Xl?NGDJcWg2KM7:TR?=MYWyOEBpMXLEUXNQMkfGTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDDSGs1N2O7Y3zpcmQyKGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhemW2aX7vZoxie3SxbXGgdIhwe3Cqb4L5cIF1cW:wIHH0JHNmejd6MB?=NVnMV3JQOjR2MUe1OlY>
MDA-MB-231NIT6PZBMcW6jc3WgRZN{[Xl?MWq1JO69VQ>?NFnTS2gzPCCqM4\4R2ROW09?MkT1TY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDDSGs1N2O7Y3zpcmQyKGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhemW2aX7vZoxie3SxbXGgdIhwe3Cqb4L5cIF1cW:wIHH0JHNmejd6MB?=Mon2NlQ1OTd3Nk[=
MDA-MB-231MlPJSpVv[3Srb36gRZN{[Xl?M3faXlEuOTBizszNNV\kWVZVOjRiaB?=MkPRSG1UVw>?NYjGeXl2\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppd{Bie3Onc4Pl[EBieyCSQWLQJINt\WG4YXflMWWyOFQyPzV4Nh?=
MCF7M17TTGZ2dmO2aX;uJGF{e2G7M4LielEuOTBizszNNGC2ZlQzPCCqMYTEUXNQNGjsNo9ld2W|IH7veEBqdmS3Y3WgZZBweHSxc3nzJIF{e2W|c3XkJIF{KFCDUmCgZ4xm[X[jZ3W=NUPQcIFxOjR2MUe1OlY>
MDA-MB-231NITzSIZHfW6ldHnvckBCe3OjeR?=M4fnVFAvPS1zIN88US=>M1;rV|Q5KGh?NFyyRVdFVVORMWXoZZMhdm9iQ3XscEBkgWOuZTDhdpJme3RiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKGG2IIP1Zk1IOSCyaHHz[S=>MYmyOFQyPzV4Nh?=
MCF7MlviSpVv[3Srb36gRZN{[Xl?MXKwMlUuOSEQvF2=MWK0PEBpMmDUSG1UVw>?MoLEbIF{KG6xIFPlcIwh[3mlbHWgZZJz\XO2IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCjdDDzeYIuTzFicHjhd4U>Ml;FNlQ1OTd3Nk[=
697M3X1SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUjR[JpKUUN3ME2xOFgvOzhibl2=NXjJR29pW0GQR1XS
P12-ICHIKAWAM4HIOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3fOUWlEPTB;OU[uNFQhdk1?MUfTRW5ITVJ?
NB69NGTU[4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWnRRYV3UUN3ME2xOlEvQCCwTR?=NIXqXnJUSU6JRWK=
EoL-1MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3;yT2lEPTB;MUi3MlI3KG6PNHHUU|hUSU6JRWK=
BHT-101MmXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NITRUW9KSzVyPUG5PE4zPSCwTR?=M3vaSnNCVkeHUh?=
SK-NEP-1M{nHemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFPteWpKSzVyPUKyNE4xOiCwTR?=MnrrV2FPT0WU
MHH-NB-11NHfTco5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXzJR|UxRTJ{MD6xPUBvVQ>?NWrLSIgyW0GQR1XS
AsPC-1NXHib|hGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M13TSWlEPTB;MkWyMlU{KG6PMX\TRW5ITVJ?
ES1M{DXb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWLJR|UxRTJ3Nj6yOUBvVQ>?MV;TRW5ITVJ?
LAMA-84MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIDhcmRKSzVyPUK1PE4yQSCwTR?=MkD3V2FPT0WU
MOLT-16MlvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHzKVHdKSzVyPUK1PE41QSCwTR?=MnX1V2FPT0WU
ES7NWjBUVV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NG\q[5BKSzVyPUK3N{4xQSCwTR?=NFjN[YFUSU6JRWK=
KY821MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWrsblFJUUN3ME2zNVQvOSCwTR?=MnXyV2FPT0WU
RT-112NWXSdmtuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkPaTWM2OD1|MkGuNFUhdk1?NHjlcY5USU6JRWK=
HL-60MlTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFrPNGpKSzVyPUO0NE43PiCwTR?=MUjTRW5ITVJ?
MOLT-4NHLRRnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHXqemNKSzVyPUO0OU4yOyCwTR?=NH\6No9USU6JRWK=
KARPAS-45MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH7DeJdKSzVyPUO3Ok4yPiCwTR?=MYPTRW5ITVJ?
SK-N-ASNXfQb|VUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlftTWM2OD1|OEeuPFMhdk1?NW\MdWlUW0GQR1XS
CTB-1NGPo[4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MULJR|UxRTRyNT6wNkBvVQ>?NF7LepZUSU6JRWK=
NKM-1NEnKbGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH3ZRXpKSzVyPUSxNU45QSCwTR?=MVrTRW5ITVJ?
HTC-C3MkTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV\JR|UxRTR|Mj65OUBvVQ>?MnOzV2FPT0WU
BE-13M{fiTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1f5XGlEPTB;NES0MlI4KG6PNUfiU|B6W0GQR1XS
KOSC-2NHTxWZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M17i[2lEPTB;NE[2Mlkhdk1?NE\qVnVUSU6JRWK=
NB14Mlz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYrJR|UxRTR6Mz61PEBvVQ>?M13EcnNCVkeHUh?=
CAL-27MoLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlvTTWM2OD12OUSuOVkhdk1?MWnTRW5ITVJ?
H9NFrqbHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUTJR|UxRTR7NT60N{BvVQ>?NVnRSnV2W0GQR1XS
RS4-11NV7tOVE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXTJR|UxRTVyND63N{BvVQ>?MkKxV2FPT0WU
PA-1MmDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYPOS3g2UUN3ME21NFkvQDZibl2=MkLpV2FPT0WU
MV-4-11MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHO2R3JKSzVyPUWxN{45PSCwTR?=Ml3uV2FPT0WU
OS-RC-2M1r5TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M37yUmlEPTB;NUKxMlYzKG6PM2SxbnNCVkeHUh?=
RPMI-8226MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2\oTGlEPTB;NUK2Mlg3KG6PNWHme4ZiW0GQR1XS
HGC-27NI\lSW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn;2TWM2OD13NkSuPVkhdk1?M3\1NnNCVkeHUh?=
CHP-212MlPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{X1PWlEPTB;NUmzMlU6KG6PNIj1NXJUSU6JRWK=
NB10NYjP[2xpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlnvTWM2OD13OUmuNVghdk1?NEXUXIZUSU6JRWK=
HHM1fnN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoTnTWM2OD13OUmuOFMhdk1?NV61dnh4W0GQR1XS
EW-16NEC3NIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnfJTWM2OD14MEOuOVIhdk1?M1nRb3NCVkeHUh?=
ES8NVPjOFVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHvwXW5KSzVyPU[wOU4zOSCwTR?=NXnUbolPW0GQR1XS
HAL-01NE\wN2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mkn4TWM2OD14MEWuOlchdk1?NIG2PW1USU6JRWK=
A204NFSydVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHToOWhKSzVyPU[zN{46OSCwTR?=NEXtfFJUSU6JRWK=
MHH-PREB-1MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHjy[HlKSzVyPU[zOk46QSCwTR?=M1PR[XNCVkeHUh?=
EM-2MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWnuc5lqUUN3ME22OVAvPjRibl2=MUHTRW5ITVJ?
BV-173Ml7sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF7lbnBKSzVyPU[1Nk41QCCwTR?=NIfqZnBUSU6JRWK=
ONS-76MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUHKe2RnUUN3ME22O|cvQDJibl2=M3vaenNCVkeHUh?=
KM-H2NU[yUIo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NI\MSnpKSzVyPU[5OU42PCCwTR?=NICxNWFUSU6JRWK=
D-263MGMYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NE\y[WxKSzVyPUexO{4yOiCwTR?=MmfrV2FPT0WU
ES3M2XjOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH7nZohKSzVyPUeyPE46OyCwTR?=NICxfG9USU6JRWK=
VA-ES-BJM37mRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlztTWM2OD15M{KuNlchdk1?NIroTJZUSU6JRWK=
NBsusSRNGnGS5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkDlTWM2OD15NEKuPVkhdk1?MWDTRW5ITVJ?
NCI-H520Mnq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlX0TWM2OD15NE[uOVIhdk1?NVfDUWRkW0GQR1XS
ES5M2ewWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYPJR|UxRTd3Mj64JI5ONX;vN45rW0GQR1XS
T-24M1;wbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MonXTWM2OD15N{iuO|Ehdk1?NF34[oNUSU6JRWK=
SW962MknvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVq4Snd3UUN3ME24NFgvPjNibl2=M3HrNHNCVkeHUh?=
EW-3NWHZfHZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFHBRYdKSzVyPUiwPE44PiCwTR?=NHOw[G1USU6JRWK=
RXF393MkHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGPMPJNKSzVyPUixNk44QSCwTR?=NWS3[lQ6W0GQR1XS
U251MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUPKWJFEUUN3ME24NVMvQDhibl2=NXy4eYdoW0GQR1XS
CAMA-1NGSzbpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVfJR|UxRTh|Mz65OEBvVQ>?MlfFV2FPT0WU
JVM-3NXP3WIxST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGrkS4VKSzVyPUi1NU44QCCwTR?=NUjmbJNQW0GQR1XS
COLO-800MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWj1b4hCUUN3ME24PVcvPzhibl2=MWrTRW5ITVJ?
OVCAR-5M3;1dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn7mTWM2OD17MECuNUBvVQ>?NEnjcZRUSU6JRWK=
LB1047-RCCMmjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYnJR|UxRTl{Nz61OkBvVQ>?M1LBfnNCVkeHUh?=
SW954MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYPOU4VvUUN3ME25NlkvPDFibl2=MnnHV2FPT0WU
J-RT3-T3-5M4PQcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mm\oTWM2OD17M{[uNFYhdk1?NVnzNmxSW0GQR1XS
MewoMorzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MY\JR|UxRTl|Nj62JI5OM1LiZnNCVkeHUh?=
NCI-H1770NFXkdpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1fRcGlEPTB;OUSwMlU2KG6PNIO3OGxUSU6JRWK=
HO-1-N-1MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYfNelJ3UUN3ME25OlIvQDFibl2=MXTTRW5ITVJ?
HSC-3MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlfPTWM2OD17Nk[uOFghdk1?MlmxV2FPT0WU
TYK-nuM2W0OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVPJR|UxRTl7OD6yOUBvVQ>?MVXTRW5ITVJ?
KYSE-150MofSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX\lelJ1UUN3ME2xMlAxODd4IN88US=>MnPnV2FPT0WU
SN12CNYC2V2VtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mmm1TWM2OD1zLkCwPFc2KM7:TR?=M3zwWHNCVkeHUh?=
MOLT-13MkPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIX4XodKSzVyPUGuNFE1OjFizszNM3TEeXNCVkeHUh?=
TE-11M1rRNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4LGPGlEPTB;MT6wOFgyOiEQvF2=M13rRXNCVkeHUh?=
DBM17IZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MljzTWM2OD1zLkC3Nlc{KM7:TR?=MoLjV2FPT0WU
CAL-39MoDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX3JR|UxRTFwMEe1NlIh|ryPMm\HV2FPT0WU
A3-KAWNGL1WlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHnubXRKSzVyPUGuNFg1ODhizszNMYnTRW5ITVJ?
CHP-134NWTadFFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NW[0OGJTUUN3ME2xMlEyQDB5IN88US=>NV7yVXBxW0GQR1XS
TGWMlTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1jnT2lEPTB;MT6xNlM6PSEQvF2=NHO4TYtUSU6JRWK=
QIMR-WILNHzwNmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVfJR|UxRTFwMUOxN|Qh|ryPMm\DV2FPT0WU
NCI-SNU-1NWrJN2JmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoTJTWM2OD1zLkG2N|U1KM7:TR?=MnW2V2FPT0WU
CGTH-W-1NHn2S5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF7qR4pKSzVyPUGuNVcyQDZizszNMYfTRW5ITVJ?
MHH-ES-1NUj6ZYlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHmwTYZKSzVyPUGuNVc6QDZizszNM2PQNXNCVkeHUh?=
LB2241-RCCMUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4DtdmlEPTB;MT6xPFYzKM7:TR?=MWLTRW5ITVJ?
ML-2NFv0TXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYTJR|UxRTFwMkC3N|Qh|ryPM1XCeHNCVkeHUh?=
COR-L23M2r0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2DFNmlEPTB;MT6yNlk{OyEQvF2=MX;TRW5ITVJ?
BFTC-905NX7JRlB{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1Lx[2lEPTB;MT6yOFI3PyEQvF2=Mnr3V2FPT0WU
Hs-578-TMXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWDaWZIyUUN3ME2xMlI2QDF5IN88US=>MlnsV2FPT0WU
KG-1Mn\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3nZfmlEPTB;MT6yOlY5PiEQvF2=M1;1b3NCVkeHUh?=
HELNH\uPZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2LrNGlEPTB;MT6yPVM{QCEQvF2=M3yxR3NCVkeHUh?=
A549NF\OOXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnTKTWM2OD1zLkK5N|k6KM7:TR?=NYHV[Y5TW0GQR1XS
COLO-741MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHu5fo9KSzVyPUGuN|IxQDlizszNMkDGV2FPT0WU
PC-3Mnm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mm[wTWM2OD1zLkO1NlIyKM7:TR?=NVPVNZFUW0GQR1XS
HOSM2XnRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MW\JR|UxRTFwM{WyPVYh|ryPMXzTRW5ITVJ?
HT-1080MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIj0PZhKSzVyPUGuN|c2OTlizszNMlXzV2FPT0WU
TE-8MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlS1TWM2OD1zLkSxO|c1KM7:TR?=NX7h[I8{W0GQR1XS
BHYMVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWnwephFUUN3ME2xMlQ3QTJ|IN88US=>MXzTRW5ITVJ?
BB65-RCCM3fpdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYLsfWFmUUN3ME2xMlUxPTJ6IN88US=>MknlV2FPT0WU
HNMorSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXPzVGtPUUN3ME2xMlU1ODdzIN88US=>NG\CSW5USU6JRWK=
NCI-H441NYLKV2pIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkPITWM2OD1zLkW0PVA4KM7:TR?=M4XofXNCVkeHUh?=
RPMI-8866M{\DbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGXyWXlKSzVyPUGuOVg2ODdizszNM2nQRnNCVkeHUh?=
CAL-62M1LSeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYTId4lFUUN3ME2xMlYxQDZ{IN88US=>NGKwb3BUSU6JRWK=
MG-63MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWXKTmxbUUN3ME2xMlYyQDF|IN88US=>NV3hTFNQW0GQR1XS
SK-LU-1MljRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NI\0T5FKSzVyPUGuOlIyPTJizszNNHHid2RUSU6JRWK=
BCPAPM2PHU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWLJR|UxRTFwNk[0OVch|ryPMl7OV2FPT0WU
22RV1M3Lqdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4qxUWlEPTB;MT62O|g1OyEQvF2=M4TDZXNCVkeHUh?=
T47DNHvPTFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWHJR|UxRTFwNkiwOlEh|ryPNWKxfGxkW0GQR1XS
MSTO-211HNULlNGZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVHJR|UxRTFwNkm2NFMh|ryPM3nR[HNCVkeHUh?=
DELM{\mZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnH1TWM2OD1zLkewNlc{KM7:TR?=M3nDSnNCVkeHUh?=
H4NY\KV3k6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlrSTWM2OD1zLkezNlEzKM7:TR?=M4\wR3NCVkeHUh?=
CAL-51NYW0[JNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYnJR|UxRTFwN{S4OVUh|ryPMXHTRW5ITVJ?
ABC-1M4\6OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUTYT2p[UUN3ME2xMlc5PTh{IN88US=>NFOzeZFUSU6JRWK=
MZ2-MELMmfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFO2TYlKSzVyPUGuO|k2PDJizszNMWHTRW5ITVJ?
YKG-1M13VSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnP3TWM2OD1zLkixNFYyKM7:TR?=NYf4Tm1UW0GQR1XS
KM12MlnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWX3c25rUUN3ME2xMlgyPjB{IN88US=>NEDPRndUSU6JRWK=
L-363NUP1WFhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2jDeGlEPTB;MT64O|QyOiEQvF2=NHXiVGNUSU6JRWK=
KU812MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkTLTWM2OD1zLki5NlgzKM7:TR?=NFnLXGpUSU6JRWK=
LOXIMVINI\PeIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{jXZ2lEPTB;MT65NVIzQCEQvF2=NFfNN3hUSU6JRWK=
G-401NULESHJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUjHOoRSUUN3ME2xMlkzPDJ6IN88US=>NYrsSnp[W0GQR1XS
SW780MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVuxT4cxUUN3ME2xMlk3OjR4IN88US=>Ml;BV2FPT0WU
SW872M{HyPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoDQTWM2OD1zLkm4N|Mh|ryPMoSyV2FPT0WU
NB7NWXCUZRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWG5UXk2UUN3ME2xMlk6OzJ|IN88US=>Mli3V2FPT0WU
T98GMWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4HZbmlEPTB;Mj6wNFY3PiEQvF2=NWD6Xpl3W0GQR1XS
SW1710NXfaRXZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEjP[XlKSzVyPUKuNFY6PDVizszNM3TqcHNCVkeHUh?=
NCI-H1573Mn;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXLxV2JRUUN3ME2yMlA4Ojl6IN88US=>MnfPV2FPT0WU
KE-37M13SO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXzJR|UxRTJwMEi5OVEh|ryPMV7TRW5ITVJ?
786-0NIfLUodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUDJR|UxRTJwMUW0N|kh|ryPNE\mTplUSU6JRWK=
SASNG\zZpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGm1RXhKSzVyPUKuNlA{PzRizszNMmLvV2FPT0WU
CAL-54NULNNohoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH7GNlNKSzVyPUKuNlA1OTNizszNMmPOV2FPT0WU
SF268NFr2eFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWTnUlZ7UUN3ME2yMlI{OTJ{IN88US=>M1zCUXNCVkeHUh?=
SW620NYX1ZppyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF7oZ3FKSzVyPUKuNlYyPjlizszNM2HXTHNCVkeHUh?=
MN-60NF65eo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoC5TWM2OD1{LkOxNFYh|ryPMlvhV2FPT0WU
EFO-27MmPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVvJR|UxRTJwM{KwOVgh|ryPNVnZZ5RiW0GQR1XS
NCI-H747NGH6dmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWDHT3FqUUN3ME2yMlMzOTl7IN88US=>NYrIc4M6W0GQR1XS
HCC2218MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkjwTWM2OD1{LkO1N|c1KM7:TR?=MYTTRW5ITVJ?
MIA-PaCa-2MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MonDTWM2OD1{LkO2OFM4KM7:TR?=MlrHV2FPT0WU
SJSA-1Mn32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF7WbGlKSzVyPUKuN|c4QTZizszNMlXTV2FPT0WU
RKONGnp[olIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYn3V3ZOUUN3ME2yMlM5PDl4IN88US=>NXTtZ|FJW0GQR1XS
NB6NH36boJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnvCTWM2OD1{LkSwN|c1KM7:TR?=MYHTRW5ITVJ?
ES4NHW1cIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF7lTVRKSzVyPUKuOFU1OjJizszNMmLsV2FPT0WU
EGI-1NU\tbY9nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYHJR|UxRTJwNE[4PFMh|ryPM3zMfXNCVkeHUh?=
CTV-1MkHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NES0fZFKSzVyPUKuOVI4PzNizszNMkLRV2FPT0WU
NCI-H1355NVjlbYlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIrwbVBKSzVyPUKuOVU6PTFizszNMXvTRW5ITVJ?
GT3TKBNUL2OJN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M33HOWlEPTB;Mj61PVE6QSEQvF2=NFK5XllUSU6JRWK=
SK-HEP-1MmmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXHxfopQUUN3ME2yMlU6OjZ4IN88US=>MmnBV2FPT0WU
GAMGNXzheYl{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYHJR|UxRTJwNUmzPVQh|ryPMnPkV2FPT0WU
SK-MES-1M3XSeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MULJR|UxRTJwNkG4NFMh|ryPNFXkeYdUSU6JRWK=
RO82-W-1NYLhflMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX;JR|UxRTJwNkKwOVch|ryPMljDV2FPT0WU
ECC10M1G1UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnjSTWM2OD1{LkewNlA3KM7:TR?=NV3FNJJDW0GQR1XS
MCF7NYTz[oFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHLieZRKSzVyPUKuO|E1PjRizszNMYXTRW5ITVJ?
D-283MEDMnnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYnJR|UxRTJwN{K0N{DPxE1?NHH6fnZUSU6JRWK=
RPMI-7951NV\SdY5YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmfNTWM2OD1{Lke1Olk1KM7:TR?=NXjQeFVUW0GQR1XS
Ramos-2G6-4C10NGriWFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4H0Z2lEPTB;Mj63O|A6QSEQvF2=NWrxSXBvW0GQR1XS
KGNMYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoHUTWM2OD1{LkixPFg1KM7:TR?=Ml:1V2FPT0WU
NUGC-3NIfYbXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXy4WXoyUUN3ME2yMlgzPTB3IN88US=>M{HXR3NCVkeHUh?=
NCI-H292M{fhdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn\VTWM2OD1{Lki1NFU{KM7:TR?=NF;Z[o9USU6JRWK=
BeckerMlfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV\JR|UxRTJwOUW4N|Ih|ryPNYi4V4F7W0GQR1XS
NCI-H1299NWLwdVlRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXfJR|UxRTNwMEWyOlMh|ryPNEnKdItUSU6JRWK=
ETK-1M3G0eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXS5U49MUUN3ME2zMlA2PDNizszNNEj6b29USU6JRWK=
TK10NFHXZ4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGHTNmlKSzVyPUOuNlAyPjVizszNM3fUOHNCVkeHUh?=
VMRC-RCZMn\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVXrUXRuUUN3ME2zMlM3PDh6IN88US=>MWLTRW5ITVJ?
YH-13Mn;JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2G2c2lEPTB;Mz60OFA4QSEQvF2=NXHrelE6W0GQR1XS
DU-145MojSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF32coxKSzVyPUOuOFYzPjlizszNM1;GTnNCVkeHUh?=
SW1088M17RbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MojHTWM2OD1|LkS3OFch|ryPM{TZZ3NCVkeHUh?=
HOP-92M2CzOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX3jbYh7UUN3ME2zMlUxOzR{IN88US=>NFj0S2JUSU6JRWK=
KP-N-YSNHWwN4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NI\0WldKSzVyPUOuOlIyOzlizszNNGi3RWpUSU6JRWK=
NCI-H460MoXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4K1OmlEPTB;Mz62Olc{KM7:TR?=NG\QSlFUSU6JRWK=
U-2-OSMmraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYDCTXByUUN3ME2zMlczPTN3IN88US=>MlfhV2FPT0WU
A101DNEfMdZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3vDWmlEPTB;Mz63Olk{PiEQvF2=MYDTRW5ITVJ?
MDA-MB-231M1;ldmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWXJR|UxRTNwOEG5OVEh|ryPM1\4N3NCVkeHUh?=
IST-MES1M4TQZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIf1UGxKSzVyPUOuPFMzKM7:TR?=NHX0OmlUSU6JRWK=
COR-L105MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1:xVGlEPTB;ND6wNVgh|ryPNGPrNmtUSU6JRWK=
NCI-H1437MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1PxXmlEPTB;ND6wNlMxOiEQvF2=NVvWNnpUW0GQR1XS
CAL-85-1M{G0bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVLJR|UxRTRwMEK0OlEh|ryPMo\JV2FPT0WU
MZ1-PCNHvaN|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1fKfmlEPTB;ND6xPFU2PiEQvF2=MXjTRW5ITVJ?
VM-CUB-1NW\M[4JqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoW5TWM2OD12LkOxNlg1KM7:TR?=Mm\wV2FPT0WU
CHL-1MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVjzdFJVUUN3ME20MlMzOTZ7IN88US=>MXzTRW5ITVJ?
MDA-MB-361MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYHJR|UxRTRwM{OxOVMh|ryPNV3kNVFWW0GQR1XS
NCI-H661NVTtfW1KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHu2eHFKSzVyPUSuOVAxQTJizszNMXjTRW5ITVJ?
EW-11NF73bGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUnNR2w1UUN3ME20MlUzOjNzIN88US=>NGn0Z3dUSU6JRWK=
BENNWnsWnFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXXJR|UxRTRwNUK4NVUh|ryPNVPGPZlqW0GQR1XS
BFTC-909NHXSUJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlvyTWM2OD12LkW2Nlc2KM7:TR?=M4PEWXNCVkeHUh?=
NCI-H2087MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkDrTWM2OD12LkW4NVY1KM7:TR?=Ml\GV2FPT0WU
RVH-421NVrYNJdbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYrJR|UxRTRwNk[2PUDPxE1?MWXTRW5ITVJ?
P30-OHKNWPSNJZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NITSZphKSzVyPUSuOlgxODhizszNNVO0OIQzW0GQR1XS
NCI-H28MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV\JR|UxRTRwOEG2OlEh|ryPM4\sU3NCVkeHUh?=
ES6NF36ZVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXrJR|UxRTRwOEOwNVYh|ryPMWnTRW5ITVJ?
769-PMln4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHnOS3pKSzVyPUSuPFU6OjZizszNNHTEenRUSU6JRWK=
OE33NFfqcGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYrJR|UxRTRwOEixOlEh|ryPNUGyb|UxW0GQR1XS
SW982NXW2bGwyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{TTVGlEPTB;ND65OVA3OSEQvF2=NV;yfYlZW0GQR1XS
A388MmC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFyzfGVKSzVyPUWuNFI6QDNizszNNXvPZ5l1W0GQR1XS
TI-73M3HzPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYmwWGVoUUN3ME21MlA3OTl2IN88US=>MmrGV2FPT0WU
HCT-116NFjpU5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVXFXIo3UUN3ME21MlA6QDh7IN88US=>MknFV2FPT0WU
HuP-T3NWnsRlBLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NULLXW1XUUN3ME21MlE5PzB7IN88US=>NY\PfGYzW0GQR1XS
G-402NGjVU3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYjnTm5PUUN3ME21MlE6PDF4IN88US=>NVXo[I1nW0GQR1XS
NCI-H1792MlHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV3JR|UxRTVwMkS2NlIh|ryPMlj1V2FPT0WU
NCI-H209MnLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn21TWM2OD13LkK1PVQzKM7:TR?=Mm\tV2FPT0WU
NCI-H1650MoHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2jnXWlEPTB;NT6zNFY{PCEQvF2=Mm\3V2FPT0WU
LCLC-97TM1NXjLRlBzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUWwO4p{UUN3ME21MlMyQDB6IN88US=>M1rmSHNCVkeHUh?=
S-117MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYLlPGhlUUN3ME21MlM3QTd4IN88US=>NFjp[ZBUSU6JRWK=
GI-ME-NNHWzTo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYi3VndKUUN3ME21MlM6PjhzIN88US=>NFPSeI9USU6JRWK=
NCI-H2122MlGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkHyTWM2OD13LkS5N|k4KM7:TR?=NVn4[nV3W0GQR1XS
NCI-H1793NYjFSIoxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4fwfmlEPTB;NT62O|U6OyEQvF2=NI\1cnZUSU6JRWK=
C2BBe1M{f1OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYnRV5YzUUN3ME21MlcxODh6IN88US=>M{DleXNCVkeHUh?=
TE-12MonYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIjPcIlKSzVyPUWuPFA2PTZizszNNWnzbXNvW0GQR1XS
LCLC-103HMXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M370emlEPTB;NT65NVch|ryPM2D4XnNCVkeHUh?=
A673NV\WWZBuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVr6[WlkUUN3ME21MlkyQTN{IN88US=>NWPN[I51W0GQR1XS
BB30-HNCMW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M37ZbWlEPTB;NT65PFM3KM7:TR?=NFPxfnFUSU6JRWK=
SF295NFjVWWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4PZeGlEPTB;Nj6wNFQzOiEQvF2=M1n4R3NCVkeHUh?=
KU-19-19M4jVOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEjQSG5KSzVyPU[uNFE4OzFizszNNFjZfZNUSU6JRWK=
CFPAC-1M2LCRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUG0ZVNQUUN3ME22MlA1PDR|IN88US=>MUPTRW5ITVJ?
LoVoMWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIi3b|hKSzVyPU[uNFUxPjNizszNMknrV2FPT0WU
8505CMXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1ru[GlEPTB;Nj6wO|U4OyEQvF2=M330[3NCVkeHUh?=
GMS-10MnKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Moj5TWM2OD14LkG1NFAzKM7:TR?=NX3xNlJVW0GQR1XS
Ca9-22NEnCOYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1j4[2lEPTB;Nj6xOlcyKM7:TR?=Mn65V2FPT0WU
DOKMXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWWyS252UUN3ME22MlIzODd{IN88US=>MoX0V2FPT0WU
FADUNXX4W5RRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NULHZ|ZqUUN3ME22MlI3ODN7IN88US=>NILiNplUSU6JRWK=
BxPC-3NFHNfZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGfsN2pKSzVyPU[uNlc{OiEQvF2=MXHTRW5ITVJ?
CAL-33M3PpTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWLJR|UxRTZwMkmyNFEh|ryPNGHMflRUSU6JRWK=
SHP-77NEfudFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1PlRmlEPTB;Nj6zNVUyOiEQvF2=MoqzV2FPT0WU
LXF-289Mo[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mlq3TWM2OD14LkOzOFU2KM7:TR?=M2fZZnNCVkeHUh?=
GB-1MoPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mlv2TWM2OD14LkO4NkDPxE1?NGTIPJZUSU6JRWK=
KS-1MmjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH75PHpKSzVyPU[uN|g1PDdizszNMlG5V2FPT0WU
D-502MGM{TX[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHXZXI1KSzVyPU[uOFI{PzZizszNNWDIOpdMW0GQR1XS
LAN-6MlnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3mzfWlEPTB;Nj61NVAzOyEQvF2=M1exSnNCVkeHUh?=
H-EMC-SSNHvITnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M37jb2lEPTB;Nj61OlE1PyEQvF2=M1vLUnNCVkeHUh?=
LC-2-adMYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX;JR|UxRTZwNkCwO|Yh|ryPM3nPOXNCVkeHUh?=
NCI-H1693NVPCOGNrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVfJR|UxRTZwNkKyNVUh|ryPMYTTRW5ITVJ?
SK-N-FINXvlcplKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{Hie2lEPTB;Nj63OVA1PCEQvF2=NVj1RXl4W0GQR1XS
D-423MGMkPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXPJR|UxRTZwN{[xNVch|ryPMlXwV2FPT0WU
KNS-42MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlPqTWM2OD14Lke4NVk4KM7:TR?=M{TSeXNCVkeHUh?=
GCTNUPKUplNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NETrPGFKSzVyPU[uPVM5KM7:TR?=MVzTRW5ITVJ?
DSH1NGj6U5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWG5T3ZyUUN3ME23MlA3OzNizszNMnHzV2FPT0WU
D-247MGM135TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIL5T41KSzVyPUeuNFc5QDFizszNNVnTd|M4W0GQR1XS
NCI-SNU-5M3nmbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUTJR|UxRTdwMUizO|Eh|ryPMoqzV2FPT0WU
TE-6MorMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUTJR|UxRTdwMkC2NFEh|ryPNFy5dYRUSU6JRWK=
NOMO-1M1\IcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4P5U2lEPTB;Nz6yNlEzPyEQvF2=MkLuV2FPT0WU
NB17Mn3tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX\JR|UxRTdwM{CzNFkh|ryPMo\EV2FPT0WU
EW-22Mly3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF7vPIpKSzVyPUeuN|Q{PDhizszNM{XZW3NCVkeHUh?=
EW-13MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MofHTWM2OD15LkO1NVYzKM7:TR?=NEj0NVZUSU6JRWK=
DOHH-2NVLGfZpQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmLITWM2OD15LkS0NFIh|ryPMWrTRW5ITVJ?
TGBC1TKBNX\tNWRRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFPSZ4lKSzVyPUeuOFk5QTlizszNM36xcXNCVkeHUh?=
GR-STMoHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUPJR|UxRTdwNUK1PVQh|ryPMX;TRW5ITVJ?
KYSE-520NESyO4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV7JR|UxRTdwNUW1NVUh|ryPNVHQNoNtW0GQR1XS
CAPAN-1MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX;ucoVMUUN3ME23MlU6PTFizszNMWTTRW5ITVJ?
HCE-4NUTH[ZFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV\JR|UxRTdwNkKyO|kh|ryPNV3pdZhVW0GQR1XS
MLMANUfqWm5wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmT6TWM2OD15Lk[yPVU4KM7:TR?=M{TJOHNCVkeHUh?=
HT-144NGS2OIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEOxdXlKSzVyPUeuOlU{PjhizszNNXvHfpRkW0GQR1XS
KYSE-180M3e1fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2HWNWlEPTB;Nz63NVE3QSEQvF2=NUXWZ2ZqW0GQR1XS
TE-5NEHYU2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYS4XWp1UUN3ME23Mlk2QTdzIN88US=>NVzXOnl5W0GQR1XS
IGROV-1M{DOW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVzJR|UxRTdwOUi1OVEh|ryPNED4c4tUSU6JRWK=
NCI-H1581NF7pbnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml;KTWM2OD16LkCxNkDPxE1?MmHzV2FPT0WU
SW1990NVXscZdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml7sTWM2OD16LkC0OlU6KM7:TR?=NGLPN49USU6JRWK=
EFM-19NYD0S2xNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MofkTWM2OD16LkC4OVQ2KM7:TR?=NFjO[4tUSU6JRWK=
OGR-1MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEjNWWxKSzVyPUiuOFMxOjNizszNM2K3W3NCVkeHUh?=
U-118-MGMYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3\UN2lEPTB;OD60N|Q3OyEQvF2=MYTTRW5ITVJ?
SK-OV-3NG[2WotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3TlW2lEPTB;OD60Olc3PSEQvF2=MUPTRW5ITVJ?
KNS-62MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXvJR|UxRThwNUG3OlEh|ryPM4HNUnNCVkeHUh?=
GOTONIDlNnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NITI[5FKSzVyPUiuOVc3OzVizszNM1\I[nNCVkeHUh?=
8305CMn60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUDQc256UUN3ME24MlcxPDh2IN88US=>MkPWV2FPT0WU
RPMI-2650M{Hremdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnrETWM2OD16LkexPVU2KM7:TR?=NYLKb41JW0GQR1XS
NEC8MmO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWrJR|UxRThwN{SzNFch|ryPNXnYXVFXW0GQR1XS
KYSE-450M1zrW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M13VSWlEPTB;OD64OlU1QCEQvF2=NHLUflZUSU6JRWK=
RMG-IMoTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGDGNJpKSzVyPUmuNVQxPThizszNNED2TI1USU6JRWK=
CAKI-1MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXjT[oxjUUN3ME25MlMyQTd7IN88US=>NFGzS2hUSU6JRWK=
KYSE-510M4nFcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2TDeWlEPTB;OT6zOVc4QCEQvF2=NF;uV|dUSU6JRWK=
A4-FukM2XqeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1;W[2lEPTB;OT6zOlcxOSEQvF2=NYPNeZBMW0GQR1XS
AN3-CANEHVXZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYXJR|UxRTlwNEW0OFQh|ryPNUPoPFFSW0GQR1XS
SK-N-DZNEDQe5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV72NoNsUUN3ME25MlczQDR7IN88US=>NXTxRlh2W0GQR1XS
HSC-2M3y4Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIPpRlNKSzVyPUmuO|Y3OjlizszNM{nMfXNCVkeHUh?=
EW-1MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEjSellKSzVyPUmuO|k{PjlizszNNYC3Oml{W0GQR1XS
D-566MGMYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVHJR|UxRTlwOEO2OlQh|ryPMkfWV2FPT0WU
COLO-792MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH7wZW5KSzVyPUmuPVg4PDZizszNMkn4V2FPT0WU
TE-10MoTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUH1VIY{UUN3ME2xNE4xOzl4IN88US=>Mn\qV2FPT0WU
NCI-H650MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGi4NGNKSzVyPUGwMlQzQDZizszNMWjTRW5ITVJ?
U-266M2rqVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEDyb2dKSzVyPUGwMlQ2PSEQvF2=MWHTRW5ITVJ?
Detroit562NFzlUGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH\VPWZKSzVyPUGxMlA2OTVizszNMXrTRW5ITVJ?
NH-12NYjyVmVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGWzZlhKSzVyPUGxMlE1PDZizszNMWHTRW5ITVJ?
CO-314MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml\ETWM2OD1zMT6yPFQzKM7:TR?=M{ezfXNCVkeHUh?=
IST-MEL1M2i3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX;6bFBWUUN3ME2xNU42OzJ|IN88US=>M1\VSXNCVkeHUh?=
KNS-81-FDNH[5VolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIXTcGNKSzVyPUGxMlU2OjdizszNNEPO[HFUSU6JRWK=
SW1463NH;JV3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYnJR|UxRTFzLkW5PFkh|ryPNFvtV25USU6JRWK=
NCI-H23NI\XN2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlfTTWM2OD1zMT62OVUzKM7:TR?=NGTVb|JUSU6JRWK=
SK-MEL-2M3nHNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIPJTGZKSzVyPUGxMlcyQTdizszNM3;HOHNCVkeHUh?=
NB13NYKwPHo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXfJR|UxRTF{LkG0PVUh|ryPMn22V2FPT0WU
DaoyM2LROWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIDsd4FKSzVyPUGyMlI5PTZizszNMXfTRW5ITVJ?
NCI-H1623NWDHeo5sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4[yNGlEPTB;MUKuN|gxOSEQvF2=NFjCeINUSU6JRWK=
NMC-G1M3\ofmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX;JR|UxRTF{LkexO{DPxE1?NWT3ZZI5W0GQR1XS
DK-MGM4rvT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHywPXVKSzVyPUGyMlk1QDJizszNM{e3cnNCVkeHUh?=
TCCSUPM4DlTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXvKUY1sUUN3ME2xN{4yOjh2IN88US=>MYDTRW5ITVJ?
SCC-15MnHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX\JR|UxRTF|LkK2OVEh|ryPNWfhdpFRW0GQR1XS
NOS-1M3PuOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYnLbWN4UUN3ME2xN{4zQDl|IN88US=>NFjuXnNUSU6JRWK=
RH-1MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWnJR|UxRTF|LkOwN|ch|ryPNILMT2hUSU6JRWK=
SK-MEL-3MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUXJR|UxRTF|LkO3Nlgh|ryPMl;nV2FPT0WU
NB5MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlzlTWM2OD1zMz60NFY4KM7:TR?=MmTyV2FPT0WU
SNU-387NHHQRotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVO4ZoxpUUN3ME2xN{42ODd{IN88US=>M3nFNnNCVkeHUh?=
CAL-120NWD3d3lTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{DKVWlEPTB;MUOuOlcyQCEQvF2=MVLTRW5ITVJ?
Mo-TNYP1ToNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEHHN|FKSzVyPUGzMlcxPyEQvF2=NUPJZ49vW0GQR1XS
LNCaP-Clone-FGCNIntdGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXzJR|UxRTF|Lke5PVIh|ryPMUnTRW5ITVJ?
CANNHnQOm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmO5TWM2OD1zND6wNlg5KM7:TR?=MonEV2FPT0WU
SK-MEL-30M2\6cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUDJR|UxRTF2LkC2N{DPxE1?M4O0dXNCVkeHUh?=
COLO-678MmXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHzLc5RKSzVyPUG0MlA5OjJizszNM1nQWHNCVkeHUh?=
SCC-9NIf6R|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF;hUlBKSzVyPUG0MlExOjFizszNMmO5V2FPT0WU
KINGS-1NXvzdZlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWDhXHl5UUN3ME2xOE4yPDB{IN88US=>MmPmV2FPT0WU
SL-513NUnGe4NXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MojxTWM2OD1zND6xPFch|ryPMX\TRW5ITVJ?
HLEMXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHS5Ro9KSzVyPUG0MlM5PTJizszNM3;RNnNCVkeHUh?=
SW1573NELLb3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlPaTWM2OD1zND60OFM2KM7:TR?=NHvMRpJUSU6JRWK=
KYSE-140NFrNOJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkDZTWM2OD1zND62N|I4KM7:TR?=MXHTRW5ITVJ?
SK-PN-DWNYTodI5TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnKyTWM2OD1zND64NFAyKM7:TR?=NYrQPHVWW0GQR1XS
A253MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MorRTWM2OD1zNT6wOlI2KM7:TR?=MlLxV2FPT0WU
CAL-12TM1PoTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUS4Wlk4UUN3ME2xOU41PjZ{IN88US=>MX;TRW5ITVJ?
COLO-679M3Tpemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUfJR|UxRTF3Lke2PFMh|ryPMoS3V2FPT0WU
UACC-257NVTGfZBuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlfVTWM2OD1zNj6xNlAyKM7:TR?=NHX0SlhUSU6JRWK=
U-87-MGMXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXnJR|UxRTF4LkO1NlMh|ryPNYC0OnBwW0GQR1XS
HCC1806NVu2WnhST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFnafZJKSzVyPUG2MlcxPzFizszNNEXWU4dUSU6JRWK=
NCI-H2170NWXn[ohCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4G3cGlEPTB;MUeuNlQ1QCEQvF2=MY\TRW5ITVJ?
AGSM4r6emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mom3TWM2OD1zNz6zPFA5KM7:TR?=M4OxN3NCVkeHUh?=
MEL-HOMWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX;ySVlHUUN3ME2xO{44PTB|IN88US=>M{Dod3NCVkeHUh?=
SW48NX30PZFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVnJR|UxRTF5Lke3NVYh|ryPMni5V2FPT0WU
HuP-T4NHrEZppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFPX[otKSzVyPUG4MlAzODZizszNNV3Hd2FtW0GQR1XS
NCI-H720M3Kx[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXPSdYtHUUN3ME2xPE4yPDB{IN88US=>NYfENm5lW0GQR1XS
RCC10RGBMnTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1zkNmlEPTB;MUiuNVY6PyEQvF2=NGT5cZNUSU6JRWK=
HD-MY-ZNGW5fYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXLJR|UxRTF6LkKyOVQh|ryPM17SdXNCVkeHUh?=
A427M1:0RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH2x[WlKSzVyPUG4MlUxQTRizszNNWfvdlM4W0GQR1XS
HCC2998NW\wcnRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3W0XmlEPTB;MUiuOlA2OSEQvF2=NUmzR3lkW0GQR1XS
EPLC-272HMmXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVPkcXdMUUN3ME2xPU4xPDN2IN88US=>NEfGdFlUSU6JRWK=
C32Ml7iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3[wfmlEPTB;MUmuNFQ2KM7:TR?=NYX5WIN2W0GQR1XS
UMC-11M3rYW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1vKNmlEPTB;MUmuNlEzOyEQvF2=MnjNV2FPT0WU
CaR-1NGD6SotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEPSW41KSzVyPUG5MlY5ODRizszNMWPTRW5ITVJ?
KYSE-410NYTuXZJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NI\C[Y5KSzVyPUG5MlkyOzlizszNNWnuemxiW0GQR1XS
HuCCT1NWjucmcyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4n0[mlEPTB;MkCuOlI6PCEQvF2=M1\3O3NCVkeHUh?=
LB996-RCCNWXhOWdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYjJR|UxRTJyLkexOlgh|ryPMYjTRW5ITVJ?
KYSE-70MluwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4TXSmlEPTB;MkCuPFA2QSEQvF2=NFK1UG1USU6JRWK=
CAL-72MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmfRTWM2OD1{MD65NVUh|ryPNIL6fYhUSU6JRWK=
Capan-2Mn;sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkKyTWM2OD1{MT6wOFE{KM7:TR?=M2LU[HNCVkeHUh?=
PANC-08-13NX;J[oVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkfxTWM2OD1{MT6yOVE2KM7:TR?=M{PLU3NCVkeHUh?=
SBC-1NG[1OXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFn1XJhKSzVyPUKxMlMxQDFizszNM{XRfXNCVkeHUh?=
MFM-223NFfsc2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnP5TWM2OD1{MT6zN|QzKM7:TR?=MV3TRW5ITVJ?
BB49-HNCM1S2OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3fhdGlEPTB;MkGuOVcyPiEQvF2=MYDTRW5ITVJ?
SH-4NULzeo86T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVzJR|UxRTJzLk[2NVgh|ryPMUjTRW5ITVJ?
HuO9NXLTbVk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnfXTWM2OD1{MT65PFI2KM7:TR?=M1;zN3NCVkeHUh?=
AM-38M4e3Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NU\NelJNUUN3ME2yNk4xPDh3IN88US=>MXXTRW5ITVJ?
A431NFr4bnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEi0SllKSzVyPUKzMlIyOTlizszNNHy4fmVUSU6JRWK=
YAPCMoXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkHTTWM2OD1{Mz6yOlUyKM7:TR?=MX\TRW5ITVJ?
LU-139MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{fkTWlEPTB;MkOuOFgxQSEQvF2=MWfTRW5ITVJ?
HEC-1M2rEXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF:2b3NKSzVyPUKzMlQ6OzdizszNM4TueXNCVkeHUh?=
SCC-25M4L5fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3T4UWlEPTB;MkSuN|AxPiEQvF2=NX3ENlJsW0GQR1XS
HT-29NUH0fHh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVfJR|UxRTJ2LkO4NlMh|ryPMUfTRW5ITVJ?
PC-14MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlHhTWM2OD1{ND62OVcyKM7:TR?=Mn\uV2FPT0WU
Calu-6NYDNN|RDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIiyZo5KSzVyPUK1MlUxPzFizszNMmrhV2FPT0WU
SJRH30Mn\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4fxZWlEPTB;MkWuOlQ6PiEQvF2=MnG3V2FPT0WU
ChaGo-K-1NXPwNVJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkX1TWM2OD1{Nj6xOlI6KM7:TR?=MUTTRW5ITVJ?
IA-LMM4XoeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXnJR|UxRTJ4LkO2OFUh|ryPMVfTRW5ITVJ?
GP5dNW\RSoFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWDHbI42UUN3ME2yOk41PDlzIN88US=>NWfIOmQ6W0GQR1XS
NCI-H2291M3jHO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUHJR|UxRTJ4Lk[1OFEh|ryPNH7afYhUSU6JRWK=
BALL-1MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MorrTWM2OD1{Nj65N|k4KM7:TR?=NHHud4hUSU6JRWK=
HCC1954NED4T4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWTJR|UxRTJ4Lkm4NFgh|ryPNUDLdHNpW0GQR1XS
NCI-H2452M3jHVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4XJU2lEPTB;MkeuOFE3OyEQvF2=M3rUOHNCVkeHUh?=
LU-99ANWD5SIJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MULJR|UxRTJ5LkW1PFIh|ryPNFHyOlZUSU6JRWK=
NTERA-S-cl-D1NX7LXFVQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml7TTWM2OD1{Nz63Nlk6KM7:TR?=MlrCV2FPT0WU
PANC-10-05M1HG[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml7BTWM2OD1{Nz63O|c2KM7:TR?=NX3HNnY{W0GQR1XS
NCI-H2405MnXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NI\yNo9KSzVyPUK3Mlk{QDdizszNNWHrboNiW0GQR1XS
MDA-MB-415M2nYdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkPzTWM2OD1{OD60NVM4KM7:TR?=M4CwZXNCVkeHUh?=
NCI-H2342M1vjTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M374bWlEPTB;MkiuOVI5OSEQvF2=M3f5cXNCVkeHUh?=
TGBC24TKBMl\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVzJR|UxRTJ6LkexNVch|ryPMX3TRW5ITVJ?
LU-134-AMXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEHQXGZKSzVyPUK4MlkzPjFizszNNHrjSm5USU6JRWK=
SCC-4NIjn[4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlLkTWM2OD1|MT6wOFk1KM7:TR?=M2fKU3NCVkeHUh?=
Saos-2M37IOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{\EfWlEPTB;M{GuPVMxPiEQvF2=MnTTV2FPT0WU
RERF-LC-MSM2q3[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1XIbWlEPTB;M{KuPFI{OSEQvF2=NWC0Tll2W0GQR1XS
M14NX3mRVBWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkOzTWM2OD1|Mj65O|Y1KM7:TR?=MVnTRW5ITVJ?
HPAF-IINFf4RXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFLucllKSzVyPUOzMlUxOTFizszNMYDTRW5ITVJ?
NCI-H1755MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHLwe4NKSzVyPUO0MlM{ODVizszNNETTO5VUSU6JRWK=
D-392MGMnLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYnScYxFUUN3ME2zOU45Pjd2IN88US=>Mme4V2FPT0WU
A704M2X2VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFfHVohKSzVyPUO2MlA1OjdizszNMYjTRW5ITVJ?
CP50-MEL-BNH7pZ|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYXUWHpbUUN3ME2zOk4yQTFzIN88US=>MnrOV2FPT0WU
EW-18M4DaS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFPoTmtKSzVyPUO2MlQ2OiEQvF2=MkfvV2FPT0WU
WM-115NEHvcIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXTJR|UxRTN4LkiwPVkh|ryPNFzBd2dUSU6JRWK=
LU-65MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4K2d2lEPTB;M{euNVQyPyEQvF2=MXfTRW5ITVJ?
NCI-H1563MnTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVj4[YdXUUN3ME2zO{4zPDh2IN88US=>MVzTRW5ITVJ?
DBTRG-05MGNH\4[GhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoHZTWM2OD1|OD6wOlkyKM7:TR?=NHzlfWNUSU6JRWK=
NCI-H630MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnjXTWM2OD1|OD60O|E1KM7:TR?=NYHGbpdwW0GQR1XS
NCI-H1155NV3nOlI2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFLKeoxKSzVyPUO5MlI1OiEQvF2=MULTRW5ITVJ?
OVACR-3MnLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnLHTWM2OD1|OT65NVk2KM7:TR?=NVXTUYtjW0GQR1XS
OAW-42M2W0RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkLRTWM2OD12MD60NlU5KM7:TR?=NX;MVXY3W0GQR1XS
JVM-2MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIL2em5KSzVyPUSxMlI1OTVizszNMXjTRW5ITVJ?
C3AMo\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXvJR|UxRTRzLkO0OFch|ryPMkXQV2FPT0WU
HT55MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2npTGlEPTB;NEKuNlg1OSEQvF2=M4LpO3NCVkeHUh?=
OVCAR-4Mn;2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXvYPXVXUUN3ME20Nk4zQTd2IN88US=>MljlV2FPT0WU
MEG-01NYXqNm5HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1fDbGlEPTB;NEKuOFYyPiEQvF2=NFeyNlRUSU6JRWK=
NCI-H82M3qxWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NInONnhKSzVyPUSzMlk5QTJizszNMlnmV2FPT0WU
JEG-3NI[1WFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlzmTWM2OD12ND65OFch|ryPMofKV2FPT0WU
BPH-1M4PVOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGfkdGlKSzVyPUS2MlM6QThizszNNYnjeZVwW0GQR1XS
MPP-89MlXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUjJR|UxRTR5LkK4PVgh|ryPNUPOWoxlW0GQR1XS
ALL-PONWXkZotKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2LQT2lEPTB;NEeuOFE5QCEQvF2=MX3TRW5ITVJ?
HTM3\OT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYHJR|UxRTR5LkS5NkDPxE1?MYXTRW5ITVJ?
NCI-H2347M4\icGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHjuc2VKSzVyPUS4MlA4OTVizszNMkH2V2FPT0WU
A2780NV\hOVlWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFL3ZZlKSzVyPUS5MlQzOjhizszNNXfIT5NiW0GQR1XS
KARPAS-299NIrMVZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXPJR|UxRTR7LkWxNVkh|ryPMVrTRW5ITVJ?
NCI-H1651NFzoNmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1XKNGlEPTB;NEmuPFgzOSEQvF2=Ml74V2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo PD 0332991 indicates complete tumor stasis in a MDA-MB-435 xenograft at 150 mg/kg. PD 0332991 also shows broad-spectrum antitumor activity in multiple human tumor xenografts by eliminating phospho-Rb and the proliferative marker Ki-67 from tumor tissue and down-regulation of genes under the transcriptional control of E2F. [1]
Features Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).

Protocol(Only for Reference)

Kinase Assay: [1]

Cdk Assays A stock solution of PD0332991 is prepared in DMSO. CDK assays are performed in 96-well filter plates. All CDK-cyclin kinase complexes are expressed in insect cells through baculovirus infection and purified. The substrate for the assays is a fragment (amino acids 792–928) of pRb fused to GST (GST·RB-Cterm). The total volume in each well is 0.1 mL containing a final concentration of 20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM dithiothreitol, 10 mM MgCl2, 25 μM ATP (for CDK4-cyclin D1, CDK6-cyclin D2, and CDK6-cyclin D3) or 12 μM ATP (for CDK2-cyclin E, CDK2-cyclin A, and CDC2-cyclin B) containing 0.25 μCi of [γ-32P]ATP, 20 ng of enzyme, 1 μg of GST·RB-Cterm, and PD 0332991 (0.001-0.1μM). All components except the [γ-32P]ATP are added to the wells, and the plate is placed on a plate mixer for 2 min. The reaction is started by adding the [γ-32P]ATP and the plate is incubated at 25 °C for 15 min. The reaction is terminated by addition of 0.1 mL of 20% trichloroacetic acid and the plate is kept at 4  °C for at least 1 hour to allow the substrate to precipitate. The wells are then washed 5 times with 0.2 mL of 10% trichloroacetic acid and radioactive incorporation is determined with a β plate counter.

Cell Assay: [1]

Cell lines Tumor cell lines including MDA-MB-435, ZR-75-1, T-47D, MCF-7, H1299, Colo-205, MDA-MB-468, H2009, CRRF-CEM and K562
Concentrations 0.01-1 μM
Incubation Time 24 hours
Method Cells are seeded at 2 × 104 per well in a 96-well plate and incubated overnight. PD 0332991 (0.01-1 μM) is added to the wells and incubated at 37 °C for another 24 hours. [14C]Thymidine (0.1 μCi) is added to each well and incorporation of the radiolabel is allowed to proceed for 72 hours. Incorporated radioactivity is determined with a β plate counter.

Animal Study: [1]

Animal Models Advanced stage human tumor xenografts including Colo-205, MDA-MB-435 breast, SF-295 glioblastoma, ZR-75-1 breast, PC-3 prostate, H125 lung, SW-620 colon, H23 lung and MDA-MB-468 breast (Rb negative) are established in severe combined immunodeficient mice.
Formulation Dissolved in sodium lactate buffer (50 mM, pH 4.0)
Dosages 0-150 mg/kg
Administration Given by gavage

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Fry DW, et al. Mol Cancer Ther, 2004, 3(11), 1427-1438.

[2] Menu E, et al. Cancer Res, 2008, 68(14), 5519-5523.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-30)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02730429 Not yet recruiting Endometrial Cancer Nordic Society for Gynaecologic Oncology|ENGOT|GCIG August 2016 Phase 2
NCT02778685 Not yet recruiting Estrogen Receptor Positive|HER2/Neu Negative|Postmenopausal|Recurrent Breast Carcinoma|Stage IV Breast Cancer City of Hope Medical Center|National Cancer Institute (NCI) July 2016 Phase 2
NCT02738866 Not yet recruiting Metastatic Breast Cancer Sidney Kimmel Comprehensive Cancer Center|Pfizer July 2016 Phase 2
NCT02668666 Recruiting Hormone Receptor Positive Malignant Neoplasm of Breast|Human Epidermal Growth Factor 2 Negative Carcinoma of Breast|Estrogen Receptor Positive Brea  ...more Hormone Receptor Positive Malignant Neoplasm of Breast|Human Epidermal Growth Factor 2 Negative Carcinoma of Breast|Estrogen Receptor Positive Breast Cancer|Progesterone Receptor Positive Tumor|Metastatic Breast Cancer Oana Danciu, MD|Pfizer|Hoosier Cancer Research Network|Bi  ...more Oana Danciu, MD|Pfizer|Hoosier Cancer Research Network|Big Ten Cancer Research Consortium June 2016 Phase 2
NCT02806050 Not yet recruiting Breast Cancer University Medical Center Groningen June 2016 Phase 2

view more

Chemical Information

Download Palbociclib (PD-0332991) HCl SDF
Molecular Weight (MW) 483.99
Formula

C24H29N7O2.HCl

CAS No. 827022-32-2
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 3 mg/mL warming (6.19 mM)
Water 30 mg/mL (61.98 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo Saline 20 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 6-acetyl-8-cyclopentyl-5-methyl-2-(5-(piperazin-1-yl)pyridin-2-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one hydrochloride

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related CDK Products

  • SU9516

    SU 9516 is a 3-substituted indolinone CDK inhibitor with IC50 of 22 nM, 40 nM, and 200 nM for CDK2, CDK1, and CDK4, respectively.

  • Ro-3306

    RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with Ki of 20 nM, >15-fold selectivity against a diverse panel of human kinases.

  • Purvalanol A

    Purvalanol A is a potent, and cell-permeable CDK inhibitor with IC50 of 4 nM, 70 nM, 35 nM, and 850 nM for cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, and cdk4-cyclin D1, respectively.

  • Palbociclib (PD0332991) Isethionate

    Palbociclib (PD0332991) Isethionate is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

    Features:The 1st specific inhibitor for CDK4/6 to show promise in multiple cancers.

  • Dinaciclib (SCH727965)

    Dinaciclib (SCH727965) is a novel and potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM in cell-free assays, respectively. It also blocks thymidine (dThd) DNA incorporation. Phase 3.

  • Flavopiridol (Alvocidib) HCl

    Flavopiridol HCl competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM in cell-free assays. It is 7.5-fold more selective for CDK1/2/4/6 than CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Phase 1/2.

  • Roscovitine (Seliciclib,CYC202)

    Roscovitine (Seliciclib, CYC202) is a potent and selective CDK inhibitor for Cdc2, CDK2 and CDK5 with IC50 of 0.65 μM, 0.7 μM and 0.16 μM in cell-free assays. It shows little effect on CDK4/6. Phase 2.

  • abemaciclib (LY2835219)

    LY2835219 is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM in cell-free assays, respectively. Phase 3.

  • Ribociclib (LEE011)

    Ribociclib (LEE011) is an orally available, and highly specific CDK4/6 inhibitor. Phase 3.

  • SNS-032 (BMS-387032)

    SNS-032 (BMS-387032) has firstly been described as a selective inhibitor of CDK2 with IC50 of 48 nM in cell-free assays and is 10- and 20-fold selective over CDK1/CDK4. It is also found to be sensitive to CDK7/9 with IC50 of 62 nM/4 nM, with little effect on CDK6. Phase 1.

Recently Viewed Items

Tags: buy Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl supplier | purchase Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl cost | Palbociclib (PD-0332991) HCl manufacturer | order Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us